

Ampio Pharmaceuticals, Inc.  
Form 8-K  
December 28, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): December 14, 2017**

**AMPIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in Charter)**

<b>Delaware</b>	<b>001-35182</b>	<b>26-0179592</b>
<b>(State or other jurisdiction of</b>	<b>(Commission</b>	<b>(IRS Employer</b>
<b>incorporation or organization)</b>	<b>File No.)</b>	<b>Identification No.)</b>

**373 Inverness Parkway, Suite 200**

**Englewood, Colorado 80112**

**(Address of principal executive offices, including zip code)**

**(720) 437-6500**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01**

**Other Events**

On December 14, 2017, Ampio Pharmaceuticals, Inc. (“Ampio”) issued a press release announcing the results of its Phase 3 clinical trial of Ampion for severe osteoarthritis of the knee. The Phase 3 clinical trial met its primary endpoint with 71% of Ampion treated patients meeting the OMERACT-OARSI responder criteria. Ampio plans to present a more detailed analysis of the Phase 3 and pooled data at an upcoming scientific meeting as well as submission for publication. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01**

**Financial Statements and Exhibits.**

**Exhibit Number Description**

99.1                    Press Release dated December 14, 2017

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AMPIO  
PHARMACEUTICALS, INC.**

By: /s/ Thomas E. Chilcott, III  
Thomas E. Chilcott, III  
*Chief Financial Officer*

Dated: December 28, 2017

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit</b>
<u>99.1</u>	<u>Press Release dated December 14, 2017.</u>